76
|
Shahamatifard F, Rodrigue D, Park K, Frikha S, Mighri F. Preparation and Characterization of Reduced Graphene Oxide Based Natural Rubber Nanocomposites. INT POLYM PROC 2020. [DOI: 10.1515/ipp-2020-350511] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Abstract
This work describes the effect of reduced graphene oxide (RGO) addition in natural rubber (NR). Firstly, RGO was synthesized based on the improved Hummer’s method then characterized by Fourier transform infrared spectroscopy (FTIR), X-ray photoelectron spectroscopy (XPS), and thermogravimetric analysis (TGA) to confirm that the RGO surface contains hydroxyl, epoxy, and carboxyl functional groups to improve graphene interaction with the NR matrix. In a second step, the synthesized RGO was predispersed in NR latex using the co-coagulation technique then added at different amounts (0 to 2 parts per hundred rubber (phr)) to a basic NR formulation and compounded in an internal mixer. The results show that the crosslink density of the developed NR/RGO nanocomposites increased by 65% for RGO concentration of 2.0 phr. For the same RGO concentration, a significant increase in tensile strength (53%) and Young’s modulus (31%) were also observed. Finally, a significant improvement (26%) of the thermal conductivity was obtained with the addition of only 0.5 phr of RGO.
Collapse
|
77
|
Meyer JM, Lee E, Celli A, Park K, Cho R, Lambert W, Pitchford M, Gordon M, Tsai K, Cleaver J, Arron ST, Mauro TM. CERKL is Upregulated in Cutaneous Squamous Cell Carcinoma and Maintains Cellular Sphingolipids and Resistance to Oxidative Stress. Br J Dermatol 2020:10.1111/bjd.19707. [PMID: 33270220 PMCID: PMC8172666 DOI: 10.1111/bjd.19707] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
BACKGROUND Ceramide Kinase-Like Protein (CERKL) was originally described in retinal tissue. CERKL has been shown to protect cells from oxidative stress, and mutations in CERKL underlie the inherited disease, retinitis pigmentosa. CERKL expression maintains cellular sphingolipids via an unknown mechanism. OBJECTIVES To determine whether CERKL is expressed in epidermis and cutaneous squamous cell carcinoma (cSCC) and whether CERKL expression affects cSCC sphingolipid metabolism and susceptibility to oxidative stress. METHODS CERKL expression was determined by RNA-Seq, qPCR and immunohistochemistry. CERKL was knocked down in cSCC cells using siRNA. Sphingolipid content was analyzed by liquid chromatography-mass spectrometry (LC-MS). Oxidative stress was induced by treatment with H2 O2 , and apoptosis was measured using flow cytometry to determine annexin v binding. RESULTS CERKL mRNA and protein are highly expressed in actinic keratosis and cSCC in comparison with normal epidermis. CERKL also is expressed in metabolically active epithelial cells in normal hair bulbs and sebaceous glands. CERKL knockdown in cultured cSCC cells reduces cellular sphingolipid content and enhances susceptibility to oxidative stress. CONCLUSIONS These findings suggest that CERKL may be important in cSCC progression and could lead to novel strategies for prevention and treatment of cSCC.
Collapse
|
78
|
Shahamatifard F, Rodrigue D, Park K, Frikha S, Mighri F. Preparation and Characterization of Reduced Graphene Oxide Based Natural Rubber Nanocomposites. INT POLYM PROC 2020. [DOI: 10.3139/217.3987] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
79
|
Cho B, Loong H, Tsai CM, Teo M, Park K, Kim H, Lee M, Olsen S. 308P The genomic landscape of non-small cell lung cancer (NSCLC) in East Asia using circulating tumour DNA (ctDNA) in clinical practice. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.302] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
80
|
Yang JH, Schuler M, Popat S, Miura S, Heeke S, Passaro A, de Marinis F, Park K, Kim E. 395P Afatinib in Asian and non-Asian patients (pts) with EGFR mutation positive (EGFRm+) NSCLC harboring major uncommon mutations. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.389] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
81
|
Diehl S, Joo K, Kim A, Avakian H, Kroll P, Park K, Riser D, Semenov-Tian-Shansky K, Tezgin K, Adhikari KP, Adhikari S, Amaryan MJ, Angelini G, Asryan G, Atac H, Barion L, Battaglieri M, Bedlinskiy I, Benmokhtar F, Bianconi A, Biselli AS, Bossù F, Boiarinov S, Briscoe WJ, Brooks WK, Bulumulla D, Burkert VD, Carman DS, Carvajal JC, Celentano A, Chatagnon P, Chetry T, Ciullo G, Clark L, Cole PL, Contalbrigo M, Crede V, D'Angelo A, Dashyan N, De Vita R, Defurne M, Deur A, Dilks C, Djalali C, Dupre R, Egiyan H, Ehrhart M, El Alaoui A, El Fassi L, Eugenio P, Filippi A, Forest TA, Ghandilyan Y, Gilfoyle GP, Giovanetti KL, Girod FX, Glazier DI, Golovatch E, Gothe RW, Griffioen KA, Guidal M, Guo L, Hakobyan H, Harrison N, Hattawy M, Hayward TB, Heddle D, Hicks K, Holtrop M, Ilieva Y, Ireland DG, Ishkhanov BS, Isupov EL, Jenkins D, Jo HS, Joosten S, Keller D, Khachatryan M, Khanal A, Khandaker M, Kim CW, Kim W, Kubarovsky V, Kuhn SE, Lanza L, Leali M, Lenisa P, Livingston K, MacGregor IJD, Marchand D, Markov N, Marsicano L, Mascagna V, McKinnon B, Meziani ZE, Mineeva T, Mirazita M, Mokeev V, Munoz Camacho C, Nadel-Turonski P, Niculescu G, Osipenko M, Paolone M, Pappalardo LL, Pasyuk E, Phelps W, Pogorelko O, Price JW, Prok Y, Raue BA, Ripani M, Rizzo A, Rossi P, Rowley J, Sabatié F, Salgado C, Schmidt A, Schumacher RA, Sharabian YG, Shrestha U, Soto O, Sparveris N, Stepanyan S, Stoler P, Strakovsky II, Strauch S, Tan JA, Tyler N, Ungaro M, Venturelli L, Voskanyan H, Voutier E, Watts DP, Wei X, Wood MH, Zachariou N, Zhang J, Zhao ZW. Extraction of Beam-Spin Asymmetries from the Hard Exclusive π^{+} Channel off Protons in a Wide Range of Kinematics. PHYSICAL REVIEW LETTERS 2020; 125:182001. [PMID: 33196236 DOI: 10.1103/physrevlett.125.182001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/27/2020] [Revised: 06/08/2020] [Accepted: 07/30/2020] [Indexed: 06/11/2023]
Abstract
We have measured beam-spin asymmetries to extract the sinϕ moment A_{LU}^{sinϕ} from the hard exclusive e[over →]p→e^{'}nπ^{+} reaction above the resonance region, for the first time with nearly full coverage from forward to backward angles in the center of mass. The A_{LU}^{sinϕ} moment has been measured up to 6.6 GeV^{2} in -t, covering the kinematic regimes of generalized parton distributions (GPD) and baryon-to-meson transition distribution amplitudes (TDA) at the same time. The experimental results in very forward kinematics demonstrate the sensitivity to chiral-odd and chiral-even GPDs. In very backward kinematics where the TDA framework is applicable, we found A_{LU}^{sinϕ} to be negative, while a sign change was observed near 90° in the center of mass. The unique results presented in this Letter will provide critical constraints to establish reaction mechanisms that can help to further develop the GPD and TDA frameworks.
Collapse
|
82
|
Kim M, Park K, Choi I. The metabolic suppressor 3-iodothyronamine enhances lipolysis in 3T3-L1 adipocytes via activation of the adenosine monophosphate-activated protein kinase/forkhead box O1 signaling pathway. JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY 2020; 71. [PMID: 33077693 DOI: 10.26402/jpp.2020.3.12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Received: 05/14/2020] [Accepted: 06/30/2020] [Indexed: 11/03/2022]
Abstract
Obesity is a major health concern in modern societies as it is linked to diverse chronic diseases, such as diabetes, cancer, stroke, and skeletomuscular disorders. This study aimed to investigate the lipolytic potency of the metabolic suppressor 3-iodothyronamine (T1AM) and its molecular mechanism in differentiated 3T3-L1 adipocytes. Cells stained with Oil Red O showed a remarkable accumulation of lipid droplets by 20-d post-differentiation and a plateau at 26 - 30 day. Treatment with 100 μM T1AM for 6 h increased the liberation of free fatty acids (FFAs) and glycerol (P < 0.05) detected in the culture media. However, this stimulatory effect was significantly suppressed by ATGListatin, an inhibitor of adipose triglyceride lipase (ATGL), suggesting that ATGL plays a rate-limiting role in triglyceride (TG) turnover. To understand the lipolytic mechanism, immunoblotting and confocal image analyses of the T1AM-treated and control groups were conducted. The elevated lipolysis was accompanied by increases in the phosphorylation of adenosine monophosphate-activated protein kinase (p-AMPK), nuclear localization of forkhead box O1 (FoxO1), and expression of monoacylglycerol lipase (MGL) protein (P < 0.05). Finally, the treated cells exhibited downregulated expression of acetyl-CoA carboxylase (ACC) relative to p-ACC and increased protein expression of carnitine palmitoyltransferase 1 (CPT1) (P < 0.05). Taken together, T1AM showed lipolytic potency via activation of the AMPK/FoxO1/ATGL/MGL axis for decomposing TGs to FFAs and glycerol and of the AMPK/ACC/CPT1 pathway in facilitating the mobilization of FFAs into the mitochondria, highlighting its therapeutic potential for the treatment of obesity.
Collapse
|
83
|
Abstract
Gene drive systems that propagate transgenes via super-Mendelian inheritance can potentially control insect-borne diseases and agricultural pests. However, concerns have been raised regarding unforeseen ecological consequences, and methods that prevent undesirable gene drive effects have been proposed. Here, we report a chemical-induced control of gene drive. We prepared a CRISPR-based gene drive system that can be removed by a site-specific recombinase, Rippase, the expression of which is induced by the chemical RU486 in fruit flies. Exposure of fruit flies to RU486 resulted in 7-12% removal of gene drive elements at each generation, leading to a significant reduction in gene drive-fly propagation. Mathematical modeling and simulation suggest that our system offers several advantages over a previously reported gene drive control system. Our chemical control system can provide a proof-of-principle for the reversible control of gene drive effects depending on ecological status and human needs.
Collapse
|
84
|
Hong D, Bang YJ, Barlesi F, Durm G, Falchook G, Govindan R, Dy G, Park K, Strickler J, Burns T, Kim J, Ang A, Lipford J, Ngarmchamnanrith G, Anderson A, Li B. 1257O Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1571] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
85
|
Reck M, Spira A, Besse B, Wolf J, Skoulidis F, Borghaei H, Goto K, Park K, Griesinger F, Felip E, Boyer M, Barrios C, Goss G, Yang H, Obiozor C, Ramalingam S. 1416TiP CodeBreak 200: A phase III multicenter study of sotorasib (AMG 510), a KRAS(G12C) inhibitor, versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) harboring KRAS p.G12C mutation. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1730] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
86
|
Yeo J, Park S, Jung H, Sun JM, Lee S, Ahn J, Park K, Ahn MJ. 1395P Who will maintain as long-term responders more than 3 years with first- or second-generation EGFR TKI among EGFR mutant NSCLC? Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1709] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
87
|
Nakagawa K, Nadal E, Garon E, Nishio M, Seto T, Yamamoto N, Park K, Shih JY, Frimodt-Moller B, Zimmermann A, Visseren-Grul C, Reck M. 1294P RELAY, erlotinib plus ramucirumab or placebo in untreated EGFR-mutated metastatic NSCLC: Outcomes by EGFR mutation type. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1608] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
88
|
Kim G, Yoon S, Park K, Sohn KY, Kim MH, Kim J. 576P The synergistic anticancer effect of PLAG on the PD-1 immune checkpoint inhibitor in the LLC-1 murine lung carcinoma syngeneic model. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.690] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
89
|
Yang JH, Schuler M, Popat S, Miura S, Heeke S, Passaro A, de Marinis F, Park K, Kim E. 1341P Afatinib in Asian and non-Asian patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC harboring uncommon mutations. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1655] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
90
|
Cabanillas M, Drilon A, Farago A, Brose M, McDermott R, Sohal D, Oh DY, Almubarak M, Bauman J, Chu E, Kummar S, Leyvraz S, Park K, Reeves J, Dima L, Maeda P, Rodrigues L, Brega N, Hong D, Waguespack S. 1916P Larotrectinib treatment of advanced TRK fusion thyroid cancer. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1404] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
91
|
McCoach C, Tan D, Besse B, Goto K, Zhu V, Rolfo C, Farajian S, Potter L, Kherani J, Soldatenkova V, Olek E, Lee P, Park K. 1291P Hypersensitivity reactions (HR) to selpercatinib in RET fusion+ non-small cell lung cancer (NSCLC) patients (pts) following immune checkpoint inhibition (CPI). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1605] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
92
|
Cho B, Lee K, Cho E, Kim DW, Lee JS, Han JY, Kim SW, Spira A, Haura E, Sabari J, Sanborn R, Bauml J, Gomez J, Lorenzini P, Infante J, Xie J, Haddish-Berhane N, Thayu M, Knoblauch R, Park K. 1258O Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1572] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
93
|
Loong H, Goto K, Elamin Y, Solomon B, Santini F, Soldatenkova V, Sashegyi A, Lin AB, Lin B, Wolf J, Oxnard G, Zhou C, Drilon A, Park K. 1413TiP LIBRETTO-431: Selpercatinib in treatment (Tx)-naïve patients with RET fusion-positive (RET+) non-small cell lung cancer (NSCLC). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1727] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
94
|
Cho BC, Kim DW, Batra U, Park K, Kim SW, Yang C, Jye VP, Sriuranpong V, Babu K, Amin K, Wang Y, Wang L, Bhering M, Geater SL. 1348P Efficacy and safety of ceritinib 450 mg-fed vs 750 mg-fasted in Asian patients (pts) with ALK+ non-small cell lung cancer (NSCLC) in the ASCEND-8 trial. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1662] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
95
|
Park K, Kim JJ, Oh SB, Jung K, Oh S, Park EJ, Hong Y, Kim J, Jang J, Jeon UB. 1508P Safety, efficacy, and patients' satisfaction of initial peripherally inserted central catheters compared with usual intravenous access in terminally ill cancer patients: A randomized phase II study. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.134] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
96
|
Kim SB, Keam B, Shin S, Chae Y, Seo S, Park K, Kim T, Park L, Hong SB, Lim E, Lee S, Ahn MJ. 928P Phase I dose-expansion (part II) study of ISU104 (a novel anti-ErbB3 monoclonal antibody) alone and combination with cetuximab (CET), in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1043] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
97
|
Mun GA, Moldakhan I, Serikbay AM, Kaldybekov D, Suleimenov IE, Park K. Hydrophilic interpolymer associates – the key to solving the problem of pre-biological evolution. INTERNATIONAL JOURNAL OF BIOLOGY AND CHEMISTRY 2020. [DOI: 10.26577/ijbch.2020.v13.i1.01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
98
|
Larin I, Zhang Y, Gasparian A, Gan L, Miskimen R, Khandaker M, Dale D, Danagoulian S, Pasyuk E, Gao H, Ahmidouch A, Ambrozewicz P, Baturin V, Burkert V, Clinton E, Deur A, Dolgolenko A, Dutta D, Fedotov G, Feng J, Gevorkyan S, Glamazdin A, Guo L, Isupov E, Ito MM, Klein F, Kowalski S, Kubarovsky A, Kubarovsky V, Lawrence D, Lu H, Ma L, Matveev V, Morrison B, Micherdzinska A, Nakagawa I, Park K, Pedroni R, Phelps W, Protopopescu D, Rimal D, Romanov D, Salgado C, Shahinyan A, Sober D, Stepanyan S, Tarasov VV, Taylor S, Vasiliev A, Wood M, Ye L, Zihlmann B. Precision measurement of the neutral pion lifetime. Science 2020; 368:506-509. [PMID: 32355026 DOI: 10.1126/science.aay6641] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2019] [Accepted: 03/30/2020] [Indexed: 11/02/2022]
Abstract
The explicit breaking of the axial symmetry by quantum fluctuations gives rise to the so-called axial anomaly. This phenomenon is solely responsible for the decay of the neutral pion π0 into two photons (γγ), leading to its unusually short lifetime. We precisely measured the decay width Γ of the [Formula: see text] process. The differential cross sections for π0 photoproduction at forward angles were measured on two targets, carbon-12 and silicon-28, yielding [Formula: see text], where stat. denotes the statistical uncertainty and syst. the systematic uncertainty. We combined the results of this and an earlier experiment to generate a weighted average of [Formula: see text] Our final result has a total uncertainty of 1.50% and confirms the prediction based on the chiral anomaly in quantum chromodynamics.
Collapse
|
99
|
Hwang S, Lee C, Park K, Oh S, Jeon S, Kang B, Kim Y, Oh J, Jeon SH, Satake M, Taniuchi I, Lee H, Seong RH. Twist2 promotes CD8 + T-cell differentiation by repressing ThPOK expression. Cell Death Differ 2020; 27:3053-3064. [PMID: 32424141 DOI: 10.1038/s41418-020-0560-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2019] [Revised: 04/30/2020] [Accepted: 05/06/2020] [Indexed: 11/09/2022] Open
Abstract
CD4/CD8 T-cell lineage differentiation is a key process in immune system development; however, a defined regulator(s) that converts the signal from T-cell receptor and co-receptor complexes into lineage differentiation remains unclear. Here, we show that Twist2 is a critical factor in CD4/CD8 thymocyte differentiation. Twist2 expression is differentially regulated by T-cell receptor signaling, leading to differentiation into the CD4 or CD8 lineage. Forced Twist2 expression perturbed CD4+ thymocyte differentiation while enhancing CD8+ thymocyte differentiation. Furthermore, Twist2 expression produced mature CD8+ thymocytes in B2m-/- mice, while its deficiency significantly impaired CD8+ cells in MHC class-II-/- and TCR transgenic mice, favoring CD8 T-cell differentiation. During CD8 lineage differentiation, Twist2 interacted with Runx3 to bind to the silencer region of the ThPOK locus, thereby blocking ThPOK expression. These findings indicate that Twist2 is a part of the transcription factor network controlling CD8 lineage differentiation.
Collapse
|
100
|
Kim NY, Chae D, Lee J, Kang B, Park K, Kim SY. Development of a risk scoring system for predicting acute kidney injury after minimally invasive partial and radical nephrectomy: a retrospective study. Surg Endosc 2020; 35:1626-1635. [PMID: 32297056 DOI: 10.1007/s00464-020-07545-0] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2019] [Accepted: 04/03/2020] [Indexed: 12/29/2022]
Abstract
BACKGROUND Acute kidney injury after partial or radical nephrectomy remains an unsolved problem even when using minimally invasive techniques. We aimed to identify risk factors for acute kidney injury (AKI) after minimally invasive nephrectomy and to develop a clinical risk scoring system. METHODS Medical records of 1762 patients who underwent minimally invasive laparoscopic or robot-assisted laparoscopic partial (n = 1009) or radical (n = 753) nephrectomy from December 2005 to November 2018 were reviewed. Candidate risk factors were screened using univariate analysis and ranked using linear discriminant analysis; top ranking factors were incorporated into a multivariate logistic regression model. Then, the final clinical scoring system was created based on the estimated odds ratios. RESULTS The incidence of acute kidney injury after partial or radical nephrectomy was 20.3 and 61.6%, respectively. Risk factors incorporated into the scoring system included: size of the parenchymal mass removed (3 < parenchymal mass ≤ 4 cm, 1 point; 4 < parenchymal mass ≤ 6 cm, 3 points; parenchymal mass > 6 cm, 5 points), male sex (2 points), diabetes mellitus (1 point), warm ischemia time ≥ 25 min (1 point), and immediate postoperative neutrophil count ≥ 12,000 µl-1 (1 point) in patients with partial nephrectomy, and sex (male, 10 points; female, 7 points) in patients with radical nephrectomy. For risk scores of 0-4, 5-6, 7, 8-9, and 10 points, the probabilities of acute kidney injury were approximately 10, 20, 40, 60, and 80%, respectively. The predictive accuracy of the scoring system was 0.827 (95% CI 0.789-0.865). CONCLUSION Our risk scoring system could help clinicians identify those at risk of acute kidney injury after minimally invasive partial or radical nephrectomy, thereby optimizing postoperative management.
Collapse
|